| Unlocking Insmed (INSM) International Revenues: Trends, Surprises, and Prospects |
Examine the evolution of Insmed's (INSM) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. |
zacks.com |
2025-05-13 14:21:52 |
Czytaj oryginał (ang.) |
| Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates |
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million. |
zacks.com |
2025-05-09 17:46:11 |
Czytaj oryginał (ang.) |
| Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript |
Insmed Incorporated (NASDAQ:INSM ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Bryan Dunn - Investor Relations Will Lewis - Chair and Chief Executive Officer Sara Bonstein - Chief Financial Officer Martina Flammer - Chief Medical Officer Conference Call Participants Andrea Newkirk - Goldman Sachs Jason Zemansky - Bank of America Nick Lenard - JPMorgan Joe Schwartz - Leerink Partners Ritu Baral - TD Cowen Jennifer Kim - Cantor Fitzgerald Liisa Bayko - Evercore Graig Suvannavejh - Mizuho Securities Leonid Timashev - RBC Nicole Germino - Truist Securities Maxwell Skor - Morgan Stanley Trung Huynh - UBS Emma Gutstein - Wolfe Research Operator Thank you for standing-by. My name is Amy, and I will be your conference operator for today. |
seekingalpha.com |
2025-05-08 18:55:04 |
Czytaj oryginał (ang.) |
| Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates |
Insmed (INSM) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.06 per share a year ago. |
zacks.com |
2025-05-08 13:20:59 |
Czytaj oryginał (ang.) |
| Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update |
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH Completed; Topline Data Expected in June 2025— —Enrollment Completed for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP; Topline Data Anticipated By the End of 2025— —MAA Filings for Brensocatib in Patients with Bronchiectasis Accepted by EMA and MHRA— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance Range of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— BRIDGEWATER, N.J. , May 8, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. |
prnewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline |
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:20 |
Czytaj oryginał (ang.) |
| Baron Health Care Fund Q1 2025 Top Contributors And Detractors |
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts. |
seekingalpha.com |
2025-04-29 15:30:00 |
Czytaj oryginał (ang.) |
| Insmed To Present at the BofA Securities 2025 Health Care Conference |
BRIDGEWATER, N.J. , April 29, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025, at 2:20 p.m. |
prnewswire.com |
2025-04-29 11:00:00 |
Czytaj oryginał (ang.) |
| Insmed: Poised For Transformation Beyond ARIKAYCE |
Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 results for non-cystic fibrosis bronchiectasis, with a potential FDA approval by August 2025, highlighting a significant market opportunity. Insmed's diversified pipeline, including TPIP and INS1201, reduces reliance on a single product and enhances long-term growth prospects. |
seekingalpha.com |
2025-04-25 15:58:50 |
Czytaj oryginał (ang.) |
| Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 |
BRIDGEWATER, N.J. , April 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has called all $569.5 million aggregate principal amount of its remaining outstanding 0.75% Convertible Senior Notes Due 2028 (the "Notes") (CUSIP No. |
prnewswire.com |
2025-04-24 11:00:00 |
Czytaj oryginał (ang.) |
| New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis |
—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Brensocatib 25 mg is the First Investigational Therapy for Bronchiectasis to Show a Statistically Significant Reduction in the Rate of Lung Function Decline— —Brensocatib is Currently Under Priority Review with the U.S. Food and Drug Administration— BRIDGEWATER, N.J. , April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published in the New England Journal of Medicine (NEJM). |
prnewswire.com |
2025-04-23 21:00:00 |
Czytaj oryginał (ang.) |
| Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025 |
BRIDGEWATER, N.J. , April 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2025 financial results on Thursday, May 8, 2025. |
prnewswire.com |
2025-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference |
—New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups— —Data from ASPEN Post-hoc Analysis Evaluating Changes in Lung Function in Bronchiectasis Patients Who Did or Did Not Experience Pulmonary Exacerbations in the Trial— — Data on Health Status Improvements Over Time Following Culture Conversion in Patients with Mycobacterium Avium Complex (MAC) Lung Disease— BRIDGEWATER, N.J. , March 25, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present 11 abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco. |
prnewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
BRIDGEWATER, N.J. , March 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 18 new employees. |
prnewswire.com |
2025-03-10 10:00:00 |
Czytaj oryginał (ang.) |
| Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says |
RBC Capital Markets has initiated coverage on Insmed Inc INSM, citing brensocatib's launch momentum. |
benzinga.com |
2025-02-25 18:19:47 |
Czytaj oryginał (ang.) |
| International Markets and Insmed (INSM): A Deep Dive for Investors |
Examine Insmed's (INSM) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock. |
zacks.com |
2025-02-24 12:15:24 |
Czytaj oryginał (ang.) |
| Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis |
—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J. , Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis. |
prnewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates |
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million. |
zacks.com |
2025-02-21 11:40:33 |
Czytaj oryginał (ang.) |
| Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript |
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript |
seekingalpha.com |
2025-02-20 14:50:35 |
Czytaj oryginał (ang.) |
| Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-20 12:36:12 |
Czytaj oryginał (ang.) |
| Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates |
Insmed (INSM) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to loss of $1.28 per share a year ago. |
zacks.com |
2025-02-20 11:15:30 |
Czytaj oryginał (ang.) |
| Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update |
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— —NDA for Brensocatib in Patients with Bronchiectasis Accepted by FDA and Granted Priority Review with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Study of TPIP in Patients with PAH, Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP, and Phase 3 ENCORE Study of ARIKAYCE Remain on Track for Topline Data in Mid-2025, End of 2025, and First Quarter of 2026, Respectively— —Company Ends 2024 with Approximately $1.4 Billion of Cash, Cash Equivalents, and Marketable Securities— BRIDGEWATER, N.J. , Feb. 20, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. |
prnewswire.com |
2025-02-20 09:00:00 |
Czytaj oryginał (ang.) |
| Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? |
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week. |
zacks.com |
2025-02-17 12:30:34 |
Czytaj oryginał (ang.) |
| Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024. |
zacks.com |
2025-02-17 12:20:39 |
Czytaj oryginał (ang.) |
| Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release |
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-13 13:06:29 |
Czytaj oryginał (ang.) |
| Insmed To Present at March 2025 Investor Conferences |
BRIDGEWATER, N.J. , Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 45th Annual TD Cowen Healthcare Conference in Boston, on Monday, March 3, 2025, at 9:10 a.m. |
prnewswire.com |
2025-02-11 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025 |
BRIDGEWATER, N.J. , Feb. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2024 financial results on Thursday, February 20, 2025. |
prnewswire.com |
2025-02-10 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity |
Insmed's Arikayce, a treatment for MAC and NTM lung diseases, generated $93.4m in Q3 2023, with full-year revenue guidance of $340m-$360m. Brensocatib, Insmed's lead pipeline candidate for non-CF bronchiectasis, received FDA Priority Review with a target action date of August 12, 2025. This is a potential multi-billion dollar selling asset. Brensocatib's market potential is significant, with Wall Street analysts projecting peak annual revenues exceeding $5bn, bolstering Insmed's market cap of $14.45bn. |
seekingalpha.com |
2025-02-07 12:30:05 |
Czytaj oryginał (ang.) |
| Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review |
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025. |
zacks.com |
2025-02-07 11:56:21 |
Czytaj oryginał (ang.) |
| Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
BRIDGEWATER, N.J. , Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 66 new employees. |
prnewswire.com |
2025-02-07 10:00:00 |
Czytaj oryginał (ang.) |
| FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025 |
—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J. , Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis. |
prnewswire.com |
2025-02-06 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference |
--ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and $425 Million, Reflecting Continued Double-Digit Growth Compared to 2024-- --NDA for Brensocatib in Bronchiectasis Submitted to FDA in December 2024, Narrowing the Timing for Expected U.S. Launch to the Third Quarter of 2025, Pending Approval Under Priority Review-- --Enrollment for Phase 2 Study of TPIP in Patients with PAH Completed in December 2024; Expected Timing for Topline Data Moved Forward to Mid-2025-- --Phase 3 ENCORE Trial for ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Fully Enrolled; Topline Data Anticipated in First Quarter of 2026-- --IND Cleared for Insmed's First Gene Therapy (INS1201) for Patients with DMD; First Patient Dosing Anticipated in the First Half of 2025-- BRIDGEWATER, N.J. , Jan. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today provided an update on the Company's commercial and clinical programs and its outlook for 2025. |
prnewswire.com |
2025-01-10 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
BRIDGEWATER, N.J. , Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 19 new employees. |
prnewswire.com |
2025-01-03 18:05:00 |
Czytaj oryginał (ang.) |
| Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference |
BRIDGEWATER, N.J. , Jan. 2, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 43rd Annual J.P. |
prnewswire.com |
2025-01-02 10:00:00 |
Czytaj oryginał (ang.) |
| 5 Biotech Breakthrough Stocks to Watch in 2025 |
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services. |
zacks.com |
2024-12-23 12:40:34 |
Czytaj oryginał (ang.) |
| Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
BRIDGEWATER, N.J. , Dec. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 30 new employees. |
prnewswire.com |
2024-12-06 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed To Present at December 2024 Investor Conferences |
BRIDGEWATER, N.J. , Dec. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Evercore ISI HealthCONx Conference in Coral Gables, Florida, on Wednesday, December 4, 2024, at 11:15 a.m. |
prnewswire.com |
2024-12-02 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data |
Insmed Incorporated's ARIKAYCE, approved for MAC lung disease, achieved strong revenue growth in Q3 of 2024 and potential for expanded FDA approval, boosting its market opportunity. Brensocatib's NDA filing for bronchiectasis is expected in Q4 2024 and could lead to a U.S. launch by mid-2025. Top-line results from the phase 2b study, using TPIP for the treatment of patients with PAH, expected in the 2nd half of 2025. |
seekingalpha.com |
2024-11-20 16:09:16 |
Czytaj oryginał (ang.) |
| Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
BRIDGEWATER, N.J. , Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 27 new employees. |
prnewswire.com |
2024-11-07 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed To Present at November 2024 Investor Conferences |
BRIDGEWATER, N.J. , Nov. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference in Boston on Monday, November 11, 2024, at 1:00 p.m. |
prnewswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| Insmed (INSM) Reliance on International Sales: What Investors Need to Know |
Review Insmed's (INSM) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock. |
zacks.com |
2024-11-04 12:22:40 |
Czytaj oryginał (ang.) |
| Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates |
INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label. |
zacks.com |
2024-11-01 11:46:24 |
Czytaj oryginał (ang.) |
| Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript |
Insmed Incorporated (NASDAQ:INSM ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Bryan Dunn – Head of Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Joe Schwartz – Leerink Partners Jessica Fye – JPMorgan Nicole Germino – Truist Securities Jason Zemansky – Bank of America Jennifer Kim – Cantor Jeff Hung – Morgan Stanley Leon Wang – Barclays Steve Willey – Stifel Graig Suvannavejh – Mizuho Operator Thank you for standing by. My name is Jeannie, and I will be your conference operator today. |
seekingalpha.com |
2024-10-31 16:31:09 |
Czytaj oryginał (ang.) |
| Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-10-31 13:01:17 |
Czytaj oryginał (ang.) |
| Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates |
Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago. |
zacks.com |
2024-10-31 11:16:07 |
Czytaj oryginał (ang.) |
| Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update |
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025— —Expanded U.S. Sales Force is Now Fully Deployed; Focusing on Bronchiectasis Disease-State Awareness and Supporting the Growth of ARIKAYCE Prior to the Anticipated Launch of Brensocatib— —Ends the Third Quarter with ~$1.5 Billion in Cash, Cash Equivalents, and Marketable Securities— —Renegotiates Term Loan with Pharmakon Resulting in a Lower Cost of Capital and an Additional $150 Million in Proceeds to be Received in the Fourth Quarter— —Reiterates 2024 Global ARIKAYCE Revenue Guidance in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023— BRIDGEWATER, N.J. , Oct. 31, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. |
prnewswire.com |
2024-10-31 09:00:00 |
Czytaj oryginał (ang.) |
| Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024. |
zacks.com |
2024-10-30 12:20:28 |
Czytaj oryginał (ang.) |
| Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List |
—Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J. , Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. |
prnewswire.com |
2024-10-24 20:05:00 |
Czytaj oryginał (ang.) |
| Insmed Unites Across Communities Around the World During Third Annual Global Day of Good |
Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J. , Oct. 23, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its third annual Global Day of Good, with more than 1,000 employees volunteering simultaneously in their respective communities around the world. |
prnewswire.com |
2024-10-23 12:00:00 |
Czytaj oryginał (ang.) |
| Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-17 15:05:47 |
Czytaj oryginał (ang.) |
| Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024 |
BRIDGEWATER, N.J. , Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2024 financial results on Thursday, October 31, 2024. |
prnewswire.com |
2024-10-17 12:00:00 |
Czytaj oryginał (ang.) |
| New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results |
—Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J. , Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. |
prnewswire.com |
2024-10-08 20:05:00 |
Czytaj oryginał (ang.) |